Myriad Genetics Licenses Gene for Hereditary Breast, Ovarian Cancers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Wednesday that it has obtained an exclusive license to the RAD51C gene, which has been associated with an increased risk for hereditary breast and ovarian cancers.

The license from a consortium of German researchers gives Myriad the exclusive global rights, with co-exclusive rights in Germany, to provide commercial testing for the gene.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.